EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the ADPKD methylome using nanoparticle-mediated combination therapy

Annie Trinh iD, Yi Huang iD, Hanjuan Shao, Aparna Ram, Julien Morival iD, Jonathan Wang iD, Eun Ji Chung, Timothy L Downing iD

APL Bioengineering · 01.06.2023 · 7 (2)

DOI: 10.1063/5.0151408 ↗

Kurz gefasst

Fachartikel in der Zeitschrift APL Bioengineering, online erschienen am 09.06.2023. Verfasst von Annie Trinh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, National Science Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA methylation aberrancies are found in autosomal dominant polycystic kidney disease (ADPKD), which suggests the methylome to be a promising therapeutic target. However, the impact of combining DNA methylation inhibitors (DNMTi) and ADPKD drugs in treating ADPKD and on disease-associated methylation patterns has not been fully explored. To test this, ADPKD drugs, metformin and tolvaptan (MT), were delivered in combination with DNMTi 5-aza-2′-deoxycytidine (Aza) to 2D or 3D cystic Pkd1 heterozygous renal epithelial cells (PKD1-Het cells) as free drugs or within nanoparticles to enable direct delivery for future in vivo applications. We found Aza synergizes with MT to reduce cell viability and cystic growth. Reduced representation bisulfite sequencing (RRBS) was performed across four groups: PBS, Free-Aza (Aza), Free-Aza+MT (F-MTAza), and Nanoparticle-Aza+MT (NP-MTAza). Global methylation patterns showed that while Aza alone induces a unimodal intermediate methylation landscape, Aza+MT recovers the bimodality reminiscent of somatic methylomes. Importantly, site-specific methylation changes associated with F-MTAza and NP-MTAza were largely conserved including hypomethylation at ADPKD-associated genes. Notably, we report hypomethylation of cancer-associated genes implicated in ADPKD pathogenesis as well as new target genes that may provide additional therapeutic effects. Overall, this study motivates future work to further elucidate the regulatory mechanisms of observed drug synergy and apply these combination therapies in vivo.

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.

ORCID-Profile: Annie Trinh, Yi Huang, Julien Morival, Jonathan Wang, Timothy L Downing

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS
  • National Science Foundation
  • Simons Foundation
  • National Institutes of Health
  • California Institute for Regenerative Medicine
  • Alfred E. Mann Institute for Biomedical Engineering, University of Southern California
  • Division of Materials Research

Zitieren

APA

Trinh, A., Huang, Y., Shao, H., Ram, A., Morival, J., Wang, J., Chung, E. J., & Downing, T. L. (2023). Targeting the ADPKD methylome using nanoparticle-mediated combination therapy. APL Bioengineering, 7(2). https://doi.org/10.1063/5.0151408

Vancouver

Trinh A, Huang Y, Shao H, Ram A, Morival J, Wang J, et al. Targeting the ADPKD methylome using nanoparticle-mediated combination therapy. APL Bioengineering. 2023;7(2). doi:10.1063/5.0151408

BibTeX
@article{Trinh2023,
  author = {Trinh, Annie and Huang, Yi and Shao, Hanjuan and Ram, Aparna and Morival, Julien and Wang, Jonathan and Chung, Eun Ji and Downing, Timothy L},
  title = {Targeting the ADPKD methylome using nanoparticle-mediated combination therapy},
  journal = {APL Bioengineering},
  year = {2023},
  volume = {7},
  number = {2},
  doi = {10.1063/5.0151408}
}
Kostenlos starten →